ArticleClinical, cosmetic and investigational dermatology2026
Identification and Preliminary mRNA Validation of Key Genes Associated with Tolerogenic Dendritic Cells in Keloid Based on Transcriptome Data.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Keloid is a cutaneous fibrotic disorder characterized by excessive fibrous tissue proliferation during wound healing. Tolerogenic dendritic cells (tolDCs) may participate in keloid immunopathology, but the related molecular signatures remain unclear. This study aimed to identify candidate tolDC-associated genes in keloid by integrating tolDC-related transcriptomic profiles with keloid transcriptomic datasets. Patients and Methods: Public keloid and tolDC transcriptome datasets were analyzed. Candidate genes were screened by intersecting keloid differentially expressed genes (DEGs) with tolDC-related DEGs. Key genes were selected using protein-protein interaction analysis, machine learning algorithms, expression comparison, and ROC analysis. An ANN model based on the selected genes was constructed and validated. Enrichment analysis, subcellular localization, immune infiltration analysis, regulatory network construction, drug prediction, and molecular docking were performed to explore their potential biological relevance. The expression of key genes was preliminarily validated at the mRNA level in clinical samples by RT-qPCR. Results: A total of 2,182 keloid DEGs and 3,541 tolDC-related genes were intersected, and CCL20 and NLRC4 were identified as candidate key genes. The ANN model showed potential diagnostic value for distinguishing keloid from control samples. CCL20 and NLRC4 were mainly localized in the cytoplasm and were associated with pathways including Reactome antimicrobial peptide signaling. Immune infiltration analysis showed associations with six immune cell types, including eosinophils and memory B cells. Regulatory network analysis identified 31 miRNAs potentially targeting these genes, and drug prediction suggested associations with 79 chemical compounds. RT-qPCR analysis in clinical samples supported the bioinformatics findings at the mRNA level. Conclusion: This study identified CCL20 and NLRC4 as candidate tolDC-associated genes in keloid. These genes may provide candidate diagnostic biomarkers and hypotheses for future immunomodulatory therapeutic targets in keloid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.